RSS-Feed abonnieren
DOI: 10.1160/TH14-08-0690
Impact of variables of the P-selectin – P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease
Publikationsverlauf
Received:
19. August 2014
Accepted after major revision:
27. Juli 2014
Publikationsdatum:
24. November 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/201504/lookinside/thumbnails/10-1160-th14-08-0690-1.jpg)
Summary
The formation of leukocyte-platelet aggregates (LPA), through the P-selectin – P-selectin glycoprotein ligand (PSGL)-1 axis, plays a pivotal role in atherothrombosis. In order to investigate the influence of platelet (pP-selectin) and soluble P-selectin (sP-selectin), and of variations in the genes encoding for P-selectin (SELP) and PSGL-1 (SELPLG) on LPA formation, we assessed monocyte (MPA)- and neutrophil-platelet aggregates (NPA) as well as pP-selectin by flow cytometry in 263 patients undergoing angioplasty and stenting. sP-selectin was determined by ELISA, the SELP Pro715 allele and the SELPLG Ile62 allele were determined by allele specific PCR. The Pro715 allele was significantly associated with lower levels of in vivo pP-selectin and sP-selectin, while agonists´ inducible pP-selectin was not influenced by the Pro715 allele. PP-selectin was significantly associated with MPA and NPA formation. The in vivo formation of MPA and NPA depended to 19 % and 7.4 %, respectively, on in vivo pP-selectin, irrespective of the Pro715 allele and the Ile62 allele carrier status. TRAP-6 inducible MPA and NPA depended to 34 % and 27 %, respectively, on TRAP-6 inducible pP-selectin, but were independent of the Pro715 allele carrier status. Carriers of the Ile62 allele showed a stronger correlation between TRAP-6 inducible pP-selectin and TRAP-6 inducible MPA/NPA than non-carriers. Furthermore, TRAP-6 inducible NPA were higher in Ile62 allele carriers, which suggests higher thrombin sensitivity. In conclusion, our findings point to the significant role of pP-selectin for MPA and NPA formation, while other variables like sP-selectin, the SELP Pro715 allele and the SELPLG Ile62 allele have less influence.
-
References
- 1 Stenberg PE, McEver RP, Shuman MA. et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-886.
- 2 Hattori R, Hamilton KK, Fugate RD. et al. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989; 264: 7768-7771.
- 3 Moore KL, Stults NL, Diaz S. et al. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol 1992; 118: 445-456.
- 4 Mayadas TN, Johnson RC, Rayburn H. et al. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74: 541-554.
- 5 Dole VS, Bergmeier W, Patten IS. et al. PSGL-1 regulates platelet P-selectin-mediated endothelial activation and shedding of P-selectin from activated platelets. Thromb Haemost 2007; 98: 806-812.
- 6 Engelmann B, Luther T, Muller I. Intravascular tissue factor pathway – a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 2003; 89: 3-8.
- 7 Falati S, Liu Q, Gross P. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-1598.
- 8 Losche W, Scholz T, Temmler U. et al. Platelet-derived microvesicles transfer tissue factor to monocytes but not to neutrophils. Platelets 2004; 15: 109-115.
- 9 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
- 10 Horn M, Bertling A, Brodde MF. et al. Human neutrophil alpha-defensins induce formation of fibrinogen and thrombospondin-1 amyloid-like structures and activate platelets via glycoprotein IIb/IIIa. J Thromb Haemost 2012; 10: 647-661.
- 11 Jilma-Stohlawetz P, Mannhalter C, Kaider A. et al. The association of the Thr715Pro P-selectin genotype with levels of P-selectin in platelet concentrates. Vox Sang. 2014. Epub ahead of print
- 12 Dunlop LC, Skinner MP, Bendall LJ. et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992; 175: 1147-1150.
- 13 Ushiyama S, Laue TM, Moore KL. et al. Structural and functional characterization of monomeric soluble P-selectin and comparison with membrane P-selectin. J Biol Chem 1993; 268: 15229-15237.
- 14 Kisucka J, Chauhan AK, Zhao BQ. et al. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 2009; 113: 6015-6022.
- 15 Chong BH, Murray B, Berndt MC. et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994; 83: 1535-1541.
- 16 Katayama M, Handa M, Araki Y. et al. Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol 1993; 84: 702-710.
- 17 Ay C, Jungbauer LV, Sailer T. et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem 2007; 53: 1235-1243.
- 18 Kyrle PA, Hron G, Eichinger S. et al. Circulating P-selectin and the risk of recurrent venous thromboembolism. Thromb Haemost 2007; 97: 880-883.
- 19 Blann AD, Draper Z. Platelet activation as a marker of heart attack. Clin Chim Acta 2011; 412: 841-842.
- 20 Skripchenko A, Kurtz J, Moroff G. et al. Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage. Transfusion 2008; 48: 1469-1477.
- 21 Stohlawetz P, Hergovich N, Stiegler G. et al. Differential induction of P-selectin expression on platelets by two cell separators during plateletpheresis and the effect of gender on the release of soluble P-selectin. Transfusion 1998; 38: 24-30.
- 22 Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005; 25: 1321-1324.
- 23 Tregouet DA, Barbaux S, Escolano S. et al. Specific haplotypes of the P-selectin gene are associated with myocardial infarction. Hum Mol Genet 2002; 11: 2015-2023.
- 24 Tregouet DA, Barbaux S, Poirier O. et al. SELPLG gene polymorphisms in relation to plasma SELPLG levels and coronary artery disease. Ann Hum Genet 2003; 67: 504-511.
- 25 Bugert P, Vosberg M, Entelmann M. et al. Polymorphisms in the P-selectin (CD62P) and P-selectin glycoprotein ligand-1 (PSGL-1) genes and coronary heart disease. Clin Chem Lab Med 2004; 42: 997-1004.
- 26 Ay C, Jungbauer LV, Kaider A. et al. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. Thromb Haemost 2008; 99: 899-904.
- 27 Volcik KA, Ballantyne CM, Coresh J. et al. Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2007; 195: e76-e82.
- 28 Lozano ML, Gonzalez-Conejero R, Corral J. et al. Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. Br J Haematol 2001; 115: 969-976.
- 29 Gremmel T, Kopp CW, Steiner S. et al. The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patients. Atherosclerosis 2011; 217: 135-138.
- 30 Panzer S, Stegfellner M, Jungbauer L. et al. Combined effects of genetic polymorphisms of P-selectin and P-selectin glycoprotein ligand-1 on the binding of platelets to monocytes. Thromb Res 2010; 125: 475-477.
- 31 Gremmel T, Eslam RB, Koppensteiner R. et al. Prasugrel reduces agonists´ inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Cardiovasc Ther 2013; 31: e40-e45.
- 32 Gremmel T, Steiner S, Seidinger D. et al. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost 2014; 111: 474-482.
- 33 Gremmel T, Durstberger M, Eichelberger B. et al. Human neutrophil alpha-defensins are associated with adenosine diphosphate-inducible neutrophil-platelet aggregate formation and response to clopidogrel in patients with atherosclerosis. Trans Res 2014; 164: 202-208.
- 34 Gould TJ, Vu T, Swystun LL. et al. Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and Platelet-Independent Mechanisms. Arterioscler Thromb Vasc Biol 2014; 34: 1977-1984.
- 35 McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86: 746-756.
- 36 Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-495.
- 37 Jurk K, Jahn UR, Van Aken H. et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seventransmembrane thrombin receptor (PAR-1). Thromb Haemost 2004; 91: 334-344.
- 38 Ofosu FA, Dewar L, Craven SJ. et al. Coordinate activation of human platelet protease-activated receptor-1 and –4 in response to subnanomolar alphathrombin. J Biol Chem 2008; 283: 26886-26893.
- 39 Gremmel T, Kopp CW, Seidinger D. et al. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. Eur J Clin Invest 2013; 43: 689-697.
- 40 Gremmel T, Calatzis A, Steiner S. et al. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?. Platelets 2010; 21: 515-521.
- 41 Badr Eslam R, Lang IM, Koppensteiner R. et al. Residual platelet activation through protease-activated receptors (PAR)-1 and –4 in patients on P2Y12 inhibitors. Int J Cardiol 2013; 168: 403-406.
- 42 Gawaz M, Stellos K, Langer HF. Platelets modulate atherogenesis and progression of atherosclerotic plaques via interaction with progenitor and dendritic cells. J Thromb Haemost 2008; 06: 235-242.
- 43 Manthey HD, Zernecke A. Dendritic cells in atherosclerosis: functions in immune regulation and beyond. Thromb Haemost 2011; 106: 772-778.
- 44 Jongstra-Bilen J, Haidari M, Zhu SN. et al. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 2006; 203: 2073-2083.
- 45 Maître B, Mangin PH, Eckly A. et al. Immature myeloid dendritic cells capture and remove activated platelets from preformed aggregates. J Thromb Haemost 2010; 08: 2262-2272.
- 46 Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.